Otsuka buys Avanir for $3.5 billion
December 3, 2014Sales and Marketing Abilify, Alzheimer's, Alzheimer’s, Nuedexta, Otsuka, Parkinson's, Parkinson’s, avanir
Otsuka is to buy Avanir Pharmaceuticals for $3.5 billion as it looks to make up for the imminent patent expiry …
‘Postcode lottery’ still cause of many lung cancer deaths
December 3, 2014Research and Development, Sales and Marketing DoH, Roche, astranzeneca, lung cancer, nlca, oncology, pd-1
Patients are still pointlessly dying of lung cancer due to a ‘postcode lottery’ of services according to new results from …
EMA discussing executive director post
December 3, 2014Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing EMA, Guido Rasi, andreas pott
The European Medicines Agency has confirmed that Andreas Pott will remain in charge of the body in place of the …
MHRA approves Google gene test for UK
December 2, 2014Medical Communications, Research and Development, Sales and Marketing 23andME, DNA, FDA, MHRA, UK, US, gene, google, test
The MHRA has approved a controversial genetic test for the UK – despite it being banned by the US FDA. …
Roche buys Ariosa Diagnostics
December 2, 2014Research and Development, Sales and Marketing IPF, IQuum, InterMune, Roche, ariosa, cfdna, diabetes, genia, seragon
Roche has purchased the privately-held US company Ariosa Diagnostics for an undisclosed fee as it looks to expand further into …
FDA clears Sanofi TB drug indication
December 2, 2014Research and Development, Sales and Marketing Bedaquiline, FDA, Sanofi, WHO, priftin, rifapentine, sirturo
The FDA has approved Sanofi’s Priftin for a new tuberculosis (TB) indication following a priority review from the regulator. Priftin …
NICE U-turn on Roche leukaemia drug
December 2, 2014Sales and Marketing Gazyvaro, MabThera, NHS, NICE, Roche, leukaemia, obinutuzumab
NICE has reversed its decision on Roche’s chronic lymphocytic leukaemia (CLL) drug Gazyvaro only two months after rejecting the drug. …
NuCana appoints GSK oncology head
December 2, 2014Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing GSK, Paolo Paoletti, biomed, nucana
Edinburgh-based clinical stage biopharma firm NuCana BioMed has appointed Dr Paolo Paoletti to its board of directors. Paoletti has been …
AZ and Lilly Alzheimer’s drug enters trials
December 1, 2014Research and Development, Sales and Marketing AZD3293, Alzheimer's, AstraZeneca, LY3314814, lilly
AstraZeneca and Eli Lilly have begun a Phase II/II trial for their Alzheimer’s treatment AZD3293 as the companies hope to …
£2 billion government plan to ‘save the NHS’
December 1, 2014Sales and Marketing Conservatives, NHS, Osborne, UK, balls, election, spending
George Osborne in his Autumn Statement on Wednesday will announce an extra £2 billion funding for the NHS in an attempt …
CRF Health expands leadership team
December 1, 2014Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing crf health, enbuska, john blakeley
Clinical trials e-solutions firm CRF Health has announced two new additions to the company’s executive leadership team. John Blakeley (pictured) …
George Freeman: UK pharma is vital for our landscape
December 1, 2014Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing ABPI, NHS, UK, WHO, freeman, medicine, stratified
The ABPI says the UK has an opportunity to benefit from stratified medicine, and the body’s 2014 conference held in …
Boehringer’s lung cancer drug Vargatef sees EU approval
November 28, 2014Sales and Marketing Boehringer, EU, Europe, IPF, NSCLC, lung cancer, nintedanib, ofev, vargatef
Boehringer Ingelheim’s nintedanib has received its second nod in Europe this month with the European Commission approving it for the …
New Teva chairman announced
November 28, 2014Manufacturing and Production, Sales and Marketing Phillip Frost, Teva, Yitzhak Peterburg, barer, generics, israel
Teva Pharmaceutical Industries has confirmed that Professor Yitzhak Peterburg is to serve as its new chairman from January. Peterburg who …
Bone Therapeutics appoints Pfizer veteran
November 28, 2014Belgium-based biotech Bone Therapeutics has appointed Dr Guy Heynen as its new chief clinical and regulatory officer. Heynen is a …
CRUK and AZ collaborate on cancer screening
November 28, 2014Research and Development, Sales and Marketing AstraZeneca, CRUK, Cambridge, Cancer, Cancer Research UK, MRC
Cancer Research UK (CRUK) scientists are to be given access to drug discovery facilities at AstraZeneca’s Cambridge site as part …
GSK Ebola vaccine ‘promising’ in early trials
November 27, 2014Research and Development, Sales and Marketing Africa, Ebola, GSK, Takeda, Vaccine, WHO, vaccines
The first trial results for GlaxoSmithKline’s (GSK) Ebola vaccine candidate have shown that the medicine was well-tolerated and produced an …
Lundbeck’s alcohol pill given NICE approval
November 27, 2014Sales and Marketing Lundbeck, NHS, NICE, alcohol, selincro
NICE has finally approved the use of Selincro (nalmefene) in order to help people who are dependent on alcohol cut …
NHS to get world’s most expensive drug
November 27, 2014Sales and Marketing Alexion, NICE, aHUS, beauchamp, blood, eculizumab, soliris
UK health watchdog NICE has recommended Alexion’s Soliris for patients with the rare disease atypical haemolytic uremic syndrome (aHUS). Soliris …
NHS needs £2 billion more in funding
November 26, 2014Medical Communications, Sales and Marketing Cameron, Hunt, Kings Fund, NHS, Osborne, king's fund, statement
Healthcare think tank the King’s Fund has called for an additional £2 billion to be injected into the NHS in …
Latest content
NIHR chief scientific adviser visits Huddersfield health innovation campus
One in three UK women with migraine say symptoms taken less seriously
Report highlights scope to expand day surgery
Sygnature formalises drug discovery collaboration with X-Chem
Codis appoints Steven Facer as chief commercial officer
